Qiagen N.V.
ISIN: NL0012169213 | Ticker: QIA | LEI: 54930036WK3GMCN17Z57
Country: Germany
QIAGEN serves more than 500,000 customers around the globe, all seeking answers from the building blocks of life – DNA, RNA and proteins. We deliver Sample to Insight solutions for molecular testing, propelling our customers from start to finish to unlock new insights. This is how we make improvements in life possible.
Our product portfolio supports our customers across the continuum of molecular testing in molecular diagnostics and life sciences. From the first important step of DNA, RNA and protein extraction from biological samples, to novel testing technologies targeting single or multiple molecular variants, and software to analyze and interpret molecular data to deliver valuable insights. Our automation systems bring together all of these steps in seamless end-to-end workflows.
1984
Served areaWorldwide
Headcount5,472
HeadquartersQiagen Str. 1, 40724 Hilden – Germany
| Line item in (usd) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Assets | N/A | 5,264,254,000.00 | 5,928,287,000.00 | 6,208,790,000.00 | 6,351,748,000.00 |
| Noncurrent Assets | N/A | 3,752,445,000.00 | 4,329,485,000.00 | 4,135,607,000.00 | 3,987,641,000.00 |
| Property Plant And Equipment | N/A | 356,100,000.00 | 427,352,000.00 | 491,357,000.00 | 492,582,000.00 |
| Goodwill | N/A | 2,166,213,000.00 | 2,389,111,000.00 | 2,376,440,000.00 | 2,380,162,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 750,599,000.00 | 883,600,000.00 | 803,192,000.00 | 748,648,000.00 |
| Investment Accounted For Using Equity Method | N/A | 9,729,000.00 | 11,017,000.00 | 21,549,000.00 | 18,217,000.00 |
| Deferred Tax Assets | N/A | 77,610,000.00 | 89,016,000.00 | 117,365,000.00 | 89,440,000.00 |
| Other Noncurrent Financial Assets | N/A | 94,187,000.00 | 4,408,000.00 | 3,945,000.00 | 5,329,000.00 |
| Noncurrent Derivative Financial Assets | N/A | 192,266,000.00 | 379,080,000.00 | 190,430,000.00 | 131,354,000.00 |
| Other Noncurrent Assets | N/A | 49,700,000.00 | 44,690,000.00 | 31,914,000.00 | 27,927,000.00 |
| Current Assets | N/A | 1,511,809,000.00 | 1,598,802,000.00 | 2,073,183,000.00 | 2,364,107,000.00 |
| Inventories | N/A | 170,704,000.00 | 291,181,000.00 | 327,525,000.00 | 358,487,000.00 |
| Trade And Other Current Receivables | N/A | 376,281,000.00 | 380,519,000.00 | 362,131,000.00 | 323,750,000.00 |
| Current Tax Assets Current | N/A | 42,119,000.00 | 59,335,000.00 | N/A | N/A |
| Other Current Financial Assets | N/A | 107,118,000.00 | 117,249,000.00 | 184,785,000.00 | 687,597,000.00 |
| Cash and cash equivalents | N/A | 622,486,000.00 | 597,003,000.00 | 879,884,000.00 | 730,271,000.00 |
| Current Restricted Cash And Cash Equivalents | N/A | 5,743,000.00 | 0.00 | N/A | N/A |
| Current Derivative Financial Assets | N/A | 107,868,000.00 | 14,127,000.00 | 175,284,000.00 | 111,617,000.00 |
| Other Current Assets | N/A | 79,490,000.00 | 198,723,000.00 | 143,574,000.00 | 152,385,000.00 |
| Equity And Liabilities | N/A | 5,264,254,000.00 | 5,928,287,000.00 | 6,208,790,000.00 | 6,351,748,000.00 |
| Equity | 2,378,815,000.00 | 2,323,847,000.00 | 2,483,049,000.00 | 2,858,892,000.00 | 3,389,293,000.00 |
| Issued Capital | N/A | 2,702,000.00 | 2,702,000.00 | 2,702,000.00 | 2,702,000.00 |
| Retained Earnings | N/A | 948,186,000.00 | 998,133,000.00 | 1,490,974,000.00 | 1,981,498,000.00 |
| Share Premium | N/A | 1,790,504,000.00 | 1,840,115,000.00 | 1,877,704,000.00 | 1,921,972,000.00 |
| Treasury Shares | N/A | 111,966,000.00 | 118,301,000.00 | 189,730,000.00 | 160,188,000.00 |
| Other Reserves | N/A | -305,579,000.00 | -239,600,000.00 | -322,758,000.00 | -356,691,000.00 |
| Noncurrent Liabilities | N/A | 1,988,913,000.00 | 2,874,343,000.00 | 1,724,053,000.00 | 1,938,163,000.00 |
| Deferred Tax Liabilities | N/A | 28,486,000.00 | 46,041,000.00 | 45,238,000.00 | 26,116,000.00 |
| Noncurrent Derivative Financial Liabilities | N/A | 435,592,000.00 | 766,410,000.00 | 429,402,000.00 | 293,725,000.00 |
| Other Noncurrent Liabilities | N/A | 106,201,000.00 | 186,724,000.00 | 209,320,000.00 | 200,475,000.00 |
| Longterm Borrowings | N/A | 1,418,634,000.00 | 1,875,168,000.00 | 1,040,093,000.00 | 1,417,847,000.00 |
| Current Liabilities | N/A | 951,494,000.00 | 570,895,000.00 | 1,625,845,000.00 | 1,024,292,000.00 |
| Current Provisions | N/A | 8,129,000.00 | 6,565,000.00 | 6,715,000.00 | 5,967,000.00 |
| Trade And Other Current Payables | N/A | 84,767,000.00 | 118,153,000.00 | 101,224,000.00 | 98,734,000.00 |
| Current Tax Liabilities Current | N/A | 34,082,000.00 | 57,676,000.00 | N/A | N/A |
| Current Derivative Financial Liabilities | N/A | 103,175,000.00 | 51,464,000.00 | 292,204,000.00 | 161,021,000.00 |
| Other Current Liabilities | N/A | 436,097,000.00 | 352,174,000.00 | 380,047,000.00 | 369,018,000.00 |
| Current Borrowings And Current Portion Of Noncurrent Borrowings | N/A | 285,244,000.00 | 42,539,000.00 | 845,655,000.00 | 389,552,000.00 |
| Line item in (usd) | 01.01.2019/ 01.01.2020 |
01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|---|
| Revenue | 1,526,424,000.00 | 1,870,346,000.00 | 2,251,657,000.00 | 2,143,020,000.00 |
| Other Income | 4,126,000.00 | 992,000.00 | 572,000.00 | 282,000.00 |
| Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 154,828,000.00 | 1,034,000.00 | 0.00 | N/A |
| Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 154,828,000.00 | 1,034,000.00 | 0.00 | N/A |
| Profit Loss From Operating Activities | -50,452,000.00 | 383,916,000.00 | 635,681,000.00 | 533,323,000.00 |
| Gains Losses On Net Monetary Position | N/A | N/A | 0.00 | -5,393,000.00 |
| Finance Income | 22,113,000.00 | 10,032,000.00 | 9,555,000.00 | 33,241,000.00 |
| Finance Costs | 75,756,000.00 | 73,002,000.00 | 56,487,000.00 | 60,090,000.00 |
| Profit Loss Before Tax | -116,721,000.00 | 154,927,000.00 | 651,102,000.00 | 666,646,000.00 |
| Income Tax Expense Continuing Operations | -46,951,000.00 | 81,287,000.00 | 114,048,000.00 | 90,985,000.00 |
| Profit (loss) | -69,770,000.00 | 73,640,000.00 | 537,054,000.00 | 575,661,000.00 |
| Line item in (usd) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | -69,770,000.00 | 73,640,000.00 | 537,054,000.00 | 575,661,000.00 |
| Adjustments For Decrease Increase In Inventories | -30,028,000.00 | -107,573,000.00 | -81,803,000.00 | -55,464,000.00 |
| Adjustments For Increase Decrease In Trade Account Payable | 9,252,000.00 | 8,442,000.00 | -5,975,000.00 | -1,756,000.00 |
| Adjustments For Depreciation And Amortisation Expense | 239,361,000.00 | 209,971,000.00 | 219,463,000.00 | 211,931,000.00 |
| Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 159,627,000.00 | 1,432,000.00 | 0.00 | 12,970,000.00 |
| Adjustments For Sharebased Payments | 65,893,000.00 | 40,936,000.00 | 38,391,000.00 | 49,507,000.00 |
| Interest Paid Classified As Operating Activities | 31,311,000.00 | 27,056,000.00 | 23,617,000.00 | 24,961,000.00 |
| Interest Received Classified As Operating Activities | 22,710,000.00 | 9,818,000.00 | 8,954,000.00 | 20,128,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | 41,474,000.00 | 42,572,000.00 | 102,083,000.00 | 98,565,000.00 |
| Cash Flows From Used In Operating Activities | 367,028,000.00 | 492,272,000.00 | 675,992,000.00 | 751,121,000.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | 68,058,000.00 | 239,572,000.00 | 0.00 | 63,651,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 60,581,000.00 | 79,908,000.00 | 138,614,000.00 | 56,338,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | 214,303,000.00 | 224,329,000.00 | 67,920,000.00 | 92,998,000.00 |
| Other Inflows Outflows Of Cash Classified As Investing Activities | -328,000.00 | -3,146,000.00 | -57,000.00 | 107,000.00 |
| Cash Flows From Used In Investing Activities | -236,958,000.00 | -453,290,000.00 | -211,701,000.00 | -735,584,000.00 |
| Proceeds From Issuing Shares | 2,075,000.00 | 7,662,000.00 | 7,919,000.00 | 121,000.00 |
| Payments To Acquire Or Redeem Entitys Shares | 74,450,000.00 | 63,995,000.00 | 99,987,000.00 | 0.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | 22,666,000.00 | 24,193,000.00 | 27,429,000.00 | 26,842,000.00 |
| Other Inflows Outflows Of Cash Classified As Financing Activities | -11,281,000.00 | -9,610,000.00 | -1,979,000.00 | 0.00 |
| Cash Flows From Used In Financing Activities | -661,746,000.00 | -74,320,000.00 | -177,795,000.00 | -152,645,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | 826,000.00 | 4,112,000.00 | -3,615,000.00 | -12,505,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | -530,850,000.00 | -31,226,000.00 | 282,881,000.00 | -149,613,000.00 |
| Cash and cash equivalents | 622,486,000.00 | 597,003,000.00 | 879,884,000.00 | 730,271,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 17.04.23 | S. Rusckowski | Non-Executive member | Other | EUR 0.00 |
| 14.03.23 | E.R. Mardis | Non-Executive member | Sell | USD 218,422.41 |
| 28.02.23 | E. Pisa | Non-Executive member | Other | USD 0.00 |
| 21.02.23 | R. Sackers | Non-Executive member | Other | USD 0.00 |
| 01.12.22 | R. Sackers | Non-Executive member | Sell | USD 1,500,000.00 |
| 31.10.22 | M. Colpan | Non-Executive member | Other | USD 0.00 |
| 08.06.22 | R. Sackers | Non-Executive member | Sell | USD 1,522,706.00 |
| 31.03.22 | R. Sackers | Non-Executive member | Other | USD 0.00 |
| 15.03.22 | R. Sackers | Non-Executive member | Other | USD 0.00 |
| 14.03.22 | E.R. Mardis | Non-Executive member | Sell | USD 228,330.77 |
NL0012169213
LEI54930036WK3GMCN17Z57
SectorHealth Care Equipment & Services
IndustryHealth Care Providers & Services
Sub-IndustryDAX
TecDAX
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.